‘Ozempic’ Shouldn’t Be a Catchall
“For now, Ozempic is like Kleenex, but we should stop using it that way,” Yasmin Tayag says.
This is an edition of The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here.
Ozempic broke out in a big way this year. By the time Jimmy Kimmel made a crack at the Oscars about the medication, bringing it a new surge of national attention, diabetes and obesity drugs that suppress appetite had been on the rise for months. I spoke with my colleague Yasmin Tayag, who covers health and science for The Atlantic, about the future potential of these drugs and the existing barriers to access.
First, here are three new stories from The Atlantic:
